Famous Patents
British merchant Peter Durand invented the tin can in 1810.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7375139 | Transdermal method and apparatus A transdermal patch for the treatment of iron deficiency including a drug reservoir layer containing an hematinic substance; a rate-controlling membrane secured to said reservoir layer; and a contact adhesive secured to said rate-controlling membrane, wherein said h... | 05/20/2008 |
| 7291592 | Method for treating patients with massive blood loss Methods for treating a mammal suffering from massive blood loss comprising administering to the mammal a polymerized hemoglobin solution. ... | 11/06/2007 |
| 7232797 | Erythropoietin dosing regimen for treating anemia The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing. ... | 06/19/2007 |
| 7135196 | Iron compositions Compositions in solid form, such as powders, comprising a mixture of a ferrous salt and a hydroxypyrone maybe used to increase the level of iron in a patient's bloodstream or to treat and/or prevent gastrointestinal infection. ... | 11/14/2006 |
| 7087223 | Preventives and/or remedies for hyperphosphatemia Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect... | 08/08/2006 |
| 6930086 | Diglycosylated erythropoietin This invention is directed to an erythropoietin mutein having in vivo biological activity for causing bone marrow cells to increase production of reticulocytes and red blood cells, in that the mutein is N-glycosylated at Asn38 and Asn83 but not N-glycosylated at Asn... | 08/16/2005 |
| 6919374 | Viscosity modulating substance and use thereof It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patient, including those suffering from sickle cell disease and plasma cell dyscrasias. Upon in vivo APM treatment patients experienced a significant l... | 07/19/2005 |
| 6897238 | Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various in... | 05/24/2005 |
| 6841172 | Method for iron delivery to a patient by transfer from dialysate The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administer... | 01/11/2005 |
| 6838079 | Methods for using the obese product to stimulate hematopoietic development The present invention relates to methods for using various forms of a novel receptor expressed by hematopoietic and endothelial cells. An additional variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. T... | 01/04/2005 |
| 6784154 | Method of use of erythropoietin to treat ischemic acute renal failure Recombinant erythropoietin is used in a method to prevent ischemic acute renal failure in patients at risk for developing ischemic acute renal failure and to treat fully-developed ischemic acute renal failure. The method is also used to prevent harmful cell apoptosi... | 08/31/2004 |
| 6770635 | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtain... | 08/03/2004 |
| 6767544 | Methods for treating cardiovascular diseases with botulinum toxin The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease. ... | 07/27/2004 |
| 6635631 | Iron compounds, compositions, methods of making the same and uses thereof The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of such complexes in the treatment and prevention of iron def... | 10/21/2003 |
| 6605588 | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof,... | 08/12/2003 |
| 6555508 | Liquid foaming soap compositions By providing a mixture of surfactants and water, with the water content ranging between bout 40% and 80% by weight based upon the weight of the entire composition, a unique, improved, liquid based foaming soap formulation is realized which is useable for ... | 04/29/2003 |
| 6534050 | 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes A pharmaceutically acceptable salt of 2-methyl-3-butenyl-1-pyrophosphoric acid; an agent for treating lymphocytes which comprises at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof, and a hydrate thereof; ... | 03/18/2003 |
| 6471500 | Process for producing erythropoietin containing no animal proteins A process for producing erythropoietin which is free of foreign animal proteins except for the proteins of the host cell, wherein DNA coding for EPO is expressed in a eukaryotic host cell and the host cell is cultured in a medium free of natural mammalian... | 10/29/2002 |
| 6399333 | Process for producing erythropoietin containing no animal proteins A process for producing erythropoietin which is free of foreign animal proteins except for the proteins of the host cell, wherein DNA coding for EPO is expressed in a eukaryotic host cell and the host cell is cultured in a medium free of natural mammalian... | 06/04/2002 |
| 6339080 | Iron compounds, compositions, methods of making the same and uses thereof The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of the complexes in the treatment and prevention of iron defi... | 01/15/2002 |
| 6333306 | Pharmaceutical combination preparations containing erythropoietin and iron preparations The present invention is directed to a pharmaceutical combination preparation comprising 2,000-7,000 U of recombinant human erythropoietin (EPO) and 5-20 mg of an Fe(III) complex, wherein the rhEPO and the Fe(III) complex may be present in separate admini... | 12/25/2001 |
| 6207651 | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 A method for orally administering vitamin preparations is described which combine vitamin B12 (B12, cobalamin) and folic acid (folate), with and without pyridoxine (B6), for preventing and treating elevated serum homocyste... | 03/27/2001 |
| 6197815 | Amino acid chelates to reduce still births and increase birth weight in non-human animals Metal amino acid chelates for animals are beneficial for facilitating and promoting growth by increasing desired metallic ion uptake. The present invention is directed to a process for providing an animal fed additive by preparing metal amino acid chelate... | 03/06/2001 |
| 6180094 | Remedies for hyperphosphatemia A medicament which comprises as an active ingredient a weakly basic anion exchange resin chelating with ferric ions, preferably a polyamine-type or an acrylic-type resin. The medicament has excellent adsorbability and selectivity to phosphate ions and eff... | 01/30/2001 |
| 6159462 | Uses of Wnt polypeptides Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation, differentiation or maintenance of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytok... | 12/12/2000 |
| 6107272 | Modified polypeptides with altered biological activity The invention relates to novel modified polypeptides, with or without variations in noncoding regions, with altered biological activity. The invention discloses methods of preparing the modified polypeptides and methods of use.... | 08/22/2000 |
| 6099830 | Methods for stimulating erythropoiesis using hematopoietic proteins Methods for stimulating erythropoiesis using the hematopoietic protein thrombopoietin, optionally in combination with erythropoietin, are provided. The methods provided may be used to stimulate erythropoiesis in bone marrow and peripheral blood cells and ... | 08/08/2000 |
| 6083984 | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in the treatment of various disorders Two new forms of prodrug for phenylacetate, of even congeners of phenylalkanoic acid and phenylalkenoic acids, which are the phenylalkanoic or phenylalkenoic esters of glycerol, or the ethyl esters of phenylalkanoic acid or phenylalkenoic acids. These for... | 07/04/2000 |
| 6060459 | Enhancing blood cell count with oxypurine nucleosides The invention relates to certain oxypurine nucleosides, congeners of such oxypurine nucleosides, and acyl derivatives thereof, and compositions which contain at least one of these compounds. The invention also relates to methods of treating or preventing ... | 05/09/2000 |
| 6060510 | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in the treatment of various disorders Two new forms of prodrug for phenylacetate, of even congeners of phenylalkanoic acid and phenylalkenoic acids, which are the phenylalkanoic or phenylalkenoic esters of glycerol, or the ethyl esters of phenylalkanoic acid or phenylalkenoic acids. These for... | 05/09/2000 |
| 6054441 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis The invention relates to certain oxypurine nucleosides, congeners of such oxypurine nucleosides, and acyl derivatives thereof, and compositions which contain at least one of these compounds. The invention also relates to methods of treating or preventing ... | 04/25/2000 |
| 6017946 | Serotonin containing formulation for oral administration and method of use A medicament containing serotonin and an antioxidant useful in the treatment of pain, including migraines and premenstrual syndrome(PMS); chronic fatigue symptoms; depression and eating disorders; and a method for increasing the serotonin level in humans ... | 01/25/2000 |
| 5985863 | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor The present invention relates to methods and pharmaceutical compositions for decreasing the production of interferon-gamma inducing factor (IGIF). The invention also relates to methods and pharmaceutical compositions for decreasing the production of inter... | 11/16/1999 |
| 5968979 | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders Two new forms of prodrug for phenylacetate, of even congeners of phenylalkanoic acid and phenylalkenoic acids, which are the phenylalkanoic or phenylalkenoic esters of glycerol, or the ethyl esters of phenylalkanoic acid or phenylalkenoic acids. These for... | 10/19/1999 |
| 5962413 | Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in comb... | 10/05/1999 |
| 5955490 | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted... | 09/21/1999 |
| 5919758 | Modified polypeptides with altered biological activity The invention relates to novel modified polypeptides, with or without variations in noncoding regions, with altered biological activity. The invention discloses methods of preparing the modified polypeptides and methods of use.... | 07/06/1999 |
| 5906978 | Method for iron delivery to a patient by transfer from dialysate The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is... | 05/25/1999 |
| 5902793 | Method for proliferating Vγ2Vδ2 T cells This invention is directed to a method for stimulating, the proliferation of Vγ2Vδ2 T cells comprising contacting Vγ2Vδ2 T cells with a Vγ2Vδ2 T cell proliferation stimulating amount of a compound selected from the group-consisting of a monoalkyl ph... | 05/11/1999 |
| 5898033 | Antigen-processing cell-targeted conjugates An anti-inflammatory conjugate including a polyamino acid backbone, a non-steroidal anti-inflammatory agent, and a moiety linking the anti-inflammatory agent to the backbone, wherein the polyamino acid backbone has a molecular weight greater than 250 kD.... | 04/27/1999 |
